# Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer

> **NCT01064310** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 169 (actual)

## Conditions studied

- Carcinoma, Renal Cell

## Interventions

- **DRUG:** pazopanib
- **DRUG:** sunitinib

## Key facts

- **NCT ID:** NCT01064310
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05-17
- **Primary completion:** 2011-10-19
- **Final completion:** 2015-11-23
- **Target enrollment:** 169 (ACTUAL)
- **Last updated:** 2017-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01064310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01064310, "Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT01064310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*